News
Sanofi and GSK agree with the UK government to supply up to 60 million doses of COVID-19 vaccine
The vaccine candidate, developed by Sanofi in partnership with GSK, is based on the recombinant protein-based technology used by Sanofi to produce an influenza vaccine, and GSK’s established pandemic adjuvant technology.
